BrowserStack, the Leading Software Testing Platform, Closes $200 Million Series B Funding at a $4 Billion Valuation
BrowserStack today announced it has secured $200 million in Series B funding at a $4 billion valuation. The round was led by BOND, with participation from Insight Partners and existing investor Accel.
BrowserStack is the global category leader in software testing on the cloud, with 50,000+ customers and four million+ developer signups. The investment will support BrowserStack's strategic acquisitions, expansion of its product offerings, and continued scale and growth.
Developer-first brand and category leader
Companies today need to release software with speed and quality to remain competitive. To do this, companies have to adopt DevOps, test more, and test fast. However, for most companies, testing remains the key bottleneck in the DevOps cycle.
BrowserStack's products help developers build bug-free software for the 5 billion internet users accessing websites and mobile applications through millions of combinations of digital environments - devices, browsers, operating systems, and versions. BrowserStack provides developers instant access to a cloud platform that allows them to comprehensively test their websites and mobile applications, replacing the need for teams to own and manage an in-house test infrastructure. This means development teams can focus on building quality software at speed rather than maintaining an in-house testing infrastructure that is complex to build and impossible to scale.
BrowserStack's platform is used by developers in over half of the Fortune 500. Its customers include leaders such as Google, Amazon, Microsoft, Twitter, Tesco, IKEA, Spotify, Expedia, and Trivago. As a developer-first brand, BrowserStack has focused on product-led growth and is profitable since its inception.
Acquisitions and new product offerings
The complexity of testing in the DevOps cycle is growing exponentially, with new classes of devices, such as Smart TVs and wearables, and new mobile devices and OS versions. Software teams also have to consider testing for new use cases such as accessibility, visual correctness, and security. BrowserStack constantly looks for ways to simplify for developers the ever-growing complexity of testing in the DevOps cycle.
"We are going to double-down on solving new developer problems in the space of DevOps testing," said Ritesh Arora, co-founder, and CEO of BrowserStack. "Our recent acquisition of Percy, a visual testing platform, was just the start. We will accelerate the rate at which we take new products to market through acquisitions and investment in our Product and Engineering teams. We want to achieve our vision of becoming the testing infrastructure for the internet."
Continued Scale and Momentum
In the last three years, BrowserStack has more than tripled its employee base to 750+ across seven countries and opened ten new data centers worldwide.
"Our global footprint of 15 data centers allows us to serve every developer from a location as close as possible to them," said Nakul Aggarwal, co-founder, and CTO of BrowserStack. "This reduces latency, which saves developers time, and helps them release fast. We will continue to invest in our platform to ensure every developer has an amazing experience."
"As software continues to rewire everything, the bar on speed and quality continues to rise, and testing software across the expanding number of browsers and devices is a huge and expensive challenge for development teams to manage on their own," says Jay Simons, General Partner at BOND. "BrowserStack makes this simple and cost-effective, giving developers instant access to the widest range of browser and device configurations to test their applications. This product is an absolute boon for today's web and app developers."
About BrowserStack
BrowserStack is the world's leading software testing platform powering over two million tests every day across 15 global data centers. We help Microsoft, Twitter, Barclays, Expedia, and over 50,000 customers deliver quality software at speed by moving testing to our Cloud. Our platform provides instant access to 2,000+ real mobile devices and browsers on a highly reliable cloud platform that effortlessly scales as testing needs grow. With BrowserStack, Dev and QA teams can move fast while delivering an amazing experience for every customer.
Founded in 2011, BrowserStack is a privately held company with offices in Dublin, San Francisco, New York, and Mumbai. For more information, visit browserstack.com or follow on Twitter @browserstack.
About BOND
BOND is a global technology investment firm that supports visionary founders throughout their entire life cycle of innovation and growth. BOND's founding partners have backed industry pioneers such as Airbnb, Canva, Docusign, DoorDash, Facebook, Instacart, JD.com, Peloton, Plaid, Ring, Slack, Spotify, Square, Stripe, Twitter, Uber, and Waze.
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than $30 billion in capital commitments. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all. For more information on Insight and all its investments, visit insightpartners.com or follow on Twitter @insightpartners.
About Accel
Accel is a global venture capital firm that is the first partner to exceptional teams everywhere, from inception through all phases of private company growth. Atlassian, Braintree, Cloudera, Crowdstrike, DJI, DocuSign, Dropbox, Etsy, Facebook, Flipkart, Freshworks, Jet, Pillpack, Qualtrics, Slack, Spotify, Supercell, Tenable, UiPath, and Venmo are among the companies Accel has backed over the past 35+ years. We help ambitious entrepreneurs build iconic global businesses. For more, visit www.accel.com or www.twitter.com/accel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005438/en/
Contact information
Media Contact
Ayushi Jain
press@browserstack.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 06:00:00 EET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 05:00:00 EET | Press release
DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digital banking capabilities and Ant International’s cutting-edge financial technologies such as AI and blockchain, to scale cross-border payments, strengthen connectivity and drive innovations in the financial ecosystem. The Memorandum of Understanding (MoU) was inked on the sidelines of the Singapore Fintech
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 02:00:00 EET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 02:00:00 EET | Press release
VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Coral NPU IP is now open-sourced on the Google Developers website and available
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 01:00:00 EET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom